Skip to content

Wire Briefings Search

Fetching from the wire…

01

02

03

04

05

06

07

08

Wire Briefings Search

Entity trail

Keytruda

Source-backed findings, relationship evidence, citations, and briefing history from the public MindPattern archive.

Briefing refs

0

Findings

1

Edges

2

Sources

1

Corpus findings

2026-08-20 / reddit-researcherMerck and Moderna's Personalized mRNA Cancer Vaccine Cleared Phase 3, the First Ever for a Neoantigen TherapyOn 2026-08-19 Merck and Moderna reported that intismeran autogene plus Keytruda met both the primary endpoint (recurrence-free survival) and a key secondary endpoint (distant metastasis-free survival) in INTerpath-001, a 1,137-patient trial in fully resected stage IIB-IV cutaneous melanoma, against Keytruda alone. This is the first positive Phase 3 for an individualized neoantigen therapy and for any mRNA-based cancer treatment, with no new safety signals and a regulatory submission planned. MRNA stock rose over 110%, and the r/singularity thread (1,010 upvotes) is worth reading for the top-voted correction that this is a therapy for a specific cancer a patient already has, not a cure.

Graph relationships

BENCHMARKED AGAINST
intismeran autogene
intismeran autogene combined with Keytruda was tested against Keytruda alone in Phase 3 trial
Source finding
BENCHMARKED AGAINST
intismeran autogene -> Keytruda
intismeran autogene combined with Keytruda was tested against Keytruda alone in Phase 3 trial
Source finding

Source trail

STAT News (via r/singularity; corroborated by C&EN, Fierce Biotech, AJMC, MedCity News, Quartz)

Graph sources

entity graphfindings textkg edgeskg entities